Rhee steps down as CEO of Korea’s SCM
Recludix, Ankyra unveil venture rounds and new execs; plus ImmunoGen, Talis, Kira, Sonoma, Spruce, Ankyra and more
BG Rhee has stepped down as CEO of SCM Lifescience Co. Ltd. (KOSDAQ:298060) to spend more time with his family. Rhee has been a leader of the Korean biotech industry for decades, where he has been president and CEO of Green Cross Corp. (KSE:006280), chairman of the Korea Biotechnology Industry Organization and a fellow of the National Academy of Engineering of Korea. Rhee is chairman of Korea's Council for Advanced Regenerative Medicine (CARM), a post he will resign at year-end, and chair of the International Vaccine Institute's Korea Support Committee.
Nancy Whiting was named CEO at Recludix Pharma Inc., which is developing therapies for cancer and inflammatory diseases. Whiting held several roles at Seattle Genetics Inc. for 15 years, most recently as EVP of corporate strategy, alliances and communications. Recludix launched with a $60 million series A round, backed by NEA, Westlake Village Biopartners, and Access Biotechnology, to initially focus on its three programs targeting STAT3, STAT6 and undisclosed non-STAT target...